ABSTRACT
BACKGROUND: Aortic regurgitation (AR) is a disease of chronic left ventricular (LV) volume overload. Over time, AR will lead to LV dilatation, hypertrophy, and loss of function. There is currently no medical treatment proven effective to slow the evolution of this cardiomyopathy. Vasodilators were once thought to have protective effects, but recent publications have cast some doubts about their effectiveness. We hypothesized that drugs targeting the renin-angiotensin system should be more effective than those having no direct effect on the renin-angiotensin system. METHODS AND RESULTS: We designed a protocol comparing the effects of 3 vasodilators in a rat AR model (n=9 to 11 animals per group). The effects of a 6-month treatment of (1) nifedipine, (2) captopril, or (3) losartan were compared in male AR rats. Sham-operated and untreated AR animals were used as controls. Nifedipine-treated animals displayed hemodynamics, LV dilatation, hypertrophy, and loss of function similar to those of the untreated group. Both captopril and losartan were effective in improving hemodynamics, slow LV dilatation, hypertrophy, and dysfunction. Gene expression analysis confirmed the lack of effects of the nifedipine treatment at the molecular level. CONCLUSIONS: Using an animal model of severe AR, we found that vasodilators targeting the renin-angiotensin system were effective to slow the development of LV remodeling and to preserve LV function. As recently shown in the most recent human clinical trial, nifedipine was totally ineffective. Targeting the renin-angiotensin system seems a promising avenue in the treatment of this disease, and clinical trials should be carefully designed to re-evaluate the effectiveness of angiotensin I-converting enzyme inhibitors or angiotensin II receptor blockers in AR.
Subject(s)
Aortic Valve Insufficiency/complications , Cardiomyopathy, Dilated/drug therapy , Hypertrophy, Left Ventricular/drug therapy , Vasodilator Agents/therapeutic use , Ventricular Function, Left/physiology , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Captopril/administration & dosage , Captopril/therapeutic use , Cardiomyopathy, Dilated/etiology , Cardiomyopathy, Dilated/physiopathology , Chronic Disease , Disease Models, Animal , Dose-Response Relationship, Drug , Echocardiography, Doppler , Follow-Up Studies , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/physiopathology , Losartan/administration & dosage , Losartan/therapeutic use , Male , Nifedipine/administration & dosage , Nifedipine/therapeutic use , Rats , Rats, Wistar , Renin-Angiotensin System/drug effects , Treatment Outcome , Vasodilator Agents/administration & dosage , Ventricular Function, Left/drug effectsABSTRACT
BACKGROUND: Past studies have suggested that the adrenergic system becomes abnormally activated in chronic volume overload, such as in severe aortic valve regurgitation (AR). However, the effectiveness of agents directed against this adrenergic activation has never been adequately tested in chronic AR. We therefore tested the effects of metoprolol treatment on the left ventricular (LV) function and remodeling in severe chronic AR in rats. METHODS AND RESULTS: Severe AR was created in adult male Wistar rats by retrograde puncture of the aortic leaflets under echocardiographic guidance. Two weeks later, some animals received metoprolol treatment (25 mg/kg) orally for 24 weeks, and some were left untreated. LV dimensions, ejection fraction, and filling parameters were evaluated by echocardiography. Hearts were harvested at 1, 2, 14, and 180 days for the evaluation of hypertrophy, beta-adrenergic receptor status, and extracellular matrix remodeling. We found that metoprolol treatment prevented LV dilatation and preserved the ejection fraction and filling parameters compared with untreated animals. Metoprolol increased the expression of beta1-adrenoreceptor mRNA and reduced G protein receptor kinase 2 levels. Collagen I and III mRNA levels were reduced. Cardiac myocyte hypertrophy was also prevented. CONCLUSIONS: In our experimental model of severe AR, metoprolol treatment had a significant beneficial global effect on LV remodeling and function. These results suggest that the adrenergic system is important in the development of volume-overload cardiomyopathy in AR and that adrenergic-blocking agents may play a role in the treatment of this disease.
Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Aortic Valve Insufficiency/drug therapy , Metoprolol/therapeutic use , Animals , Aortic Valve Insufficiency/diagnostic imaging , Aortic Valve Insufficiency/genetics , Aortic Valve Insufficiency/physiopathology , Catecholamines/analysis , Cell Size/drug effects , Chronic Disease , Drug Evaluation, Preclinical , Fibronectins/analysis , Heart Rate/drug effects , Heart Ventricles/drug effects , Heart Ventricles/pathology , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/prevention & control , Male , Metoprolol/pharmacology , Myocytes, Cardiac/chemistry , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/ultrastructure , Organ Size , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Receptors, Adrenergic, beta-1/biosynthesis , Receptors, Adrenergic, beta-1/genetics , Stroke Volume , Ultrasonography , Up-Regulation/drug effects , Ventricular Remodeling/drug effectsABSTRACT
OBJECTIVES: We studied a known rabbit model of atherosclerosis to assess the effect of a hypercholesterolemic diet on aortic valve morphology and function. We also evaluated the effects of the combination of this diet with vitamin D supplements on the development of the disease and the occurrence of valve calcification. BACKGROUND: Aortic valve stenosis (AVS) is the most common valvular heart disease. Recent observations have suggested a link between atherosclerosis and the development of AVS. However, until now, there has been no solid direct proof of this potential link. METHODS: Rabbits were divided in three groups: 1) no treatment; 2) cholesterol-enriched diet (0.5% cholesterol); and 3) cholesterol-enriched diet plus vitamin D(2) (50,000 IU/day). Echocardiographic assessment of the aortic valve was done at baseline and after 12 weeks of treatment. The aortic valve area (AVA) and maximal and mean transvalvular gradients were recorded and compared over time. RESULTS: Control animals displayed no abnormalities of the aortic valve. Despite important increases in blood total cholesterol levels, animals in group 2 did not develop any significant functional aortic valve abnormality over 12 weeks. However, eight of 10 of the animals in group 3 developed a significant decrease in AVA (p = 0.004) and significant increases in transvalvular gradients (p = 0.003). CONCLUSIONS: This study supports a potential link between atherosclerosis and the development of AVS. The differences noted between hypercholesterolemic animals with or without vitamin D(2) supplementation imply a significant role of calcium in the development of AVS, meriting further attention.